Alnylam Pharmaceuticals, Inc.
ALNY
$248.13
-$1.10-0.44%
| Weiss Ratings | ALNY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | ALNY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Fair | |||
| Volatility Index | Fair | |||
| Beta / Standard Deviation | ALNY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.24 | |||
| Price History | ALNY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 1.19% | |||
| 30-Day Total Return | -6.91% | |||
| 60-Day Total Return | -1.46% | |||
| 90-Day Total Return | -15.85% | |||
| Year to Date Total Return | 6.21% | |||
| 1-Year Total Return | 65.80% | |||
| 2-Year Total Return | 24.25% | |||
| 3-Year Total Return | 52.23% | |||
| 5-Year Total Return | 118.83% | |||
| 52-Week High % Change | -18.12% | |||
| 52-Week Low % Change | 75.54% | |||
| Price | ALNY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $304.39 | |||
| 52-Week Low Price | $141.98 | |||
| 52-Week Low Price (Date) | Apr 25, 2024 | |||
| 52-Week High Price (Date) | Oct 17, 2024 | |||
| Valuation | ALNY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 32.26B | |||
| Enterprise Value | 32.31B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -2.17 | |||
| Earnings Per Share Growth | -38.96% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 14.31 | |||
| Price/Book (Q) | 480.30 | |||
| Enterprise Value/Revenue (TTM) | 14.37 | |||
| Price | $248.13 | |||
| Enterprise Value/EBITDA (TTM) | -268.80 | |||
| Enterprise Value/EBIT | -182.68 | |||
| Market Cap Category | Large Cap | |||
| Dividends and Shares | ALNY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 129.12M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ALNY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 617 551 8200 | |||
| Address | 675 West Kendall Street Cambridge, MA 02142 | |||
| Website | www.alnylam.com | |||
| Country | United States | |||
| Year Founded | 2002 | |||
| Profitability | ALNY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -7.86% | |||
| Profit Margin | -12.37% | |||
| Management Effectiveness | ALNY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -2.74% | |||
| Return on Equity | -- | |||
| Income Statement | ALNY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 2.25B | |||
| Total Revenue (TTM) | 2.25B | |||
| Revenue Per Share | $17.41 | |||
| Gross Profit (TTM) | 1.92B | |||
| EBITDA (TTM) | -120.22M | |||
| EBIT (TTM) | -176.89M | |||
| Net Income (TTM) | -278.16M | |||
| Net Income Avl. to Common (TTM) | -278.16M | |||
| Total Revenue Growth (Q YOY) | 34.90% | |||
| Earnings Growth (Q YOY) | 39.24% | |||
| EPS Diluted (TTM) | -2.17 | |||
| EPS Diluted Growth (Q YOY) | 40.90% | |||
| Balance Sheet | ALNY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 2.69B | |||
| Cash Per Share (Q) | $20.87 | |||
| Total Current Assets (Q) | 3.30B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 67.09M | |||
| Current Ratio (Q) | 2.778 | |||
| Book Value Per Share (Q) | $0.52 | |||
| Total Assets (Q) | 4.24B | |||
| Total Current Liabilities (Q) | 1.19B | |||
| Total Debt (Q) | 2.74B | |||
| Total Liabilities (Q) | 4.17B | |||
| Total Common Equity (Q) | 67.09M | |||
| Cash Flow | ALNY - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -116.84M | |||
| Cash from Financing (TTM) | 294.16M | |||
| Net Change in Cash (TTM) | 153.77M | |||
| Levered Free Cash Flow (TTM) | 197.88M | |||
| Cash from Operations (TTM) | -8.31M | |||
